ORIC Pharmaceuticals(NASDAQ) ORIC

Current Price$12.27

Market Cap$1.25B

Since IPO (2020)-58%

5 Year-30%

1 Year+3%

1 Month+28%

ORIC Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 12.10	2026-07-24

ORIC Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+12.77%	USD 10.73	2026-07-17
1 month	+28.31%	USD 9.43	2026-06-24
3 month	+18.16%	USD 10.24	2026-04-24
Year to date	+47.92%	USD 8.18	2025-12-31
1 year	+3.15%	USD 11.73	2025-07-24
3 year	+40.05%	USD 8.64	2023-07-25
5 year	-29.86%	USD 17.25	2021-07-23
Since inception	-57.74%	USD 25.77	2020-04-24

ORIC Pharmaceuticals Financials at a Glance

Market Cap

$1.25B

Revenue (TTM)

$0.00

Net Income (TTM)

-$135.21M

EPS (TTM)

-$1.43

P/E Ratio

-8.46

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$12.27

Volume

3,613,187.776

Open

$10.94

Price

$12.27

Volume

3,613,187.776

Open

$10.94

Previous Close

$12.10

Daily Range

$10.74 - $12.55

52-Week Range

$7.23 - $14.93

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$12.27

Volume

3,613,187.776

Open

$10.94

Previous Close

$12.10

Daily Range

$10.74 - $12.55

52-Week Range

$7.23 - $14.93

Estimated Earnings Date

Aug 11, 2026

ORIC News

research scientists drugs pharma biotech

Why Shares of Oric Pharmaceuticals Jumped Monday

James HalleyJun 26, 2023

Why ORIC Pharmaceuticals Stock Is Crashing Today

Keith SpeightsMar 22, 2022

Will Last Week's Biotech IPO Outperform in a Recession?

David HaenApr 28, 2020

ORIC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ORIC Pharmaceuticals

ORIC Pharmaceuticals makes new drugs for people with hard-to-treat cancers. These medicines fight the ways tumors resist standard treatments. They focus on helping patients with prostate and lung cancer.

What Is in the Medicine Cabinet?

Rinzimetostat: Oral drug designed to treat advanced prostate cancer by blocking a protein complex that helps tumors grow.
Enozertinib: Brain-penetrant medicine for lung cancer patients whose tumors have specific genetic mutations.
ORIC-533: Small molecule aimed at stopping a specific enzyme from hiding cancer cells from the immune system.
Discovery Programs: Early-stage research focusing on new ways to target key biological dependencies in cancer cells.

How the Business Grew

Licensed global rights to rinzimetostat from Mirati Therapeutics in August 2020 to expand its prostate cancer pipeline.
Partnered with Voronoi Inc. in October 2020 to develop a specialized treatment for mutated lung cancer.
Signed a clinical supply agreement with Bayer in May 2024 to test drug combinations for prostate cancer.
Collaborated with Johnson & Johnson in 2024 and 2025 to evaluate combination therapies for lung and prostate cancers.
Reduced total workforce and focused spending on the two lead clinical programs in August 2025.

Standing Out From the Crowd

The company uses a precision medicine approach. This involves testing for specific biological markers to find the patients most likely to benefit from its drugs. Its leadership team includes experts who previously helped develop several major cancer drugs at other biotech firms.

By the Numbers

Operating income was -$34.6 million in Q4 2025, narrowed 12.7% from -$39.6 million in Q4 2024.
Net income reached -$30.5 million in Q4 2025, narrowed 16% year-over-year.
Free cash flow reached -$22.9 million in Q4 2025, narrowed 19.1% from the previous year.
Market capitalization reached $718.2 million in Q4 2025, up 26% from $570.2 million in Q4 2024.

Bottom Line

ORIC has transitioned from an early-stage researcher to a clinical-stage developer with two primary drug candidates in human trials. By focusing its resources on specific cancer resistance mechanisms, the company aims to extend the effectiveness of existing oncology treatments.

AI Generated • May 2, 2026

Industry

Biotechnology

Sector

Health Care

Employees

104

CEO

Jacob M. Chacko, MD, MBA

Website

www.oricpharma.com

Headquarters

South San Francisco, CA 94080, US

ORIC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-35.33%

Return on Capital

-36.12%

Return on Assets

-30.96%

Earnings Yield

-11.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.25B

Shares Outstanding

103.52M

Volume

3.61M

Avg. Volume

1.65M

Financials (TTM)

Gross Profit

-$320.00K

Operating Income

-$149.91M

EBITDA

-$134.03M

Operating Cash Flow

-$110.88M

Capital Expenditure

-$487.00K

Free Cash Flow

-$111.36M

Cash & ST Invst.

$281.93M

Total Debt

$3.30M

ORIC Pharmaceuticals Performance Analysis

ORIC Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

ORIC Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

ORIC Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.25	8.4%
2023	2023-12-31	USD -1.96	-12.9%
2024	2024-12-31	USD -1.83	-6.3%
2025	2025-12-31	USD -1.47	-19.6%

ORIC Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-11.9%
Q3	2025-09-30	29.8%
Q4	2025-12-31	9.1%
Q1	2026-03-31	-13.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.25B

N/A

Market Cap/Employee

$12.04M

N/A

Employees

104

N/A

Net Income

-$35.77M

-19.1%

EBITDA

-$35.50M

-19.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$281.93M

+38.4%

Total Debt

$3.30M

+2.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$3.30M

+2.6%

Return on Assets

-30.96%

N/A

Return on Invested Capital

-35.78%

N/A

Free Cash Flow

-$32.44M

+2.2%

Operating Cash Flow

-$32.44M

+1.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TRMLTourmaline Bio, Inc.

TRMLTourmaline Bio, Inc.$47.98+0.00%

INBXInhibrx Biosciences Inc.

INBXInhibrx Biosciences Inc.$81.55-4.06%

NKTRNektar Therapeutics

NKTRNektar Therapeutics$70.73+1.97%

AMLXAmylyx Pharmaceuticals, Inc.

AMLXAmylyx Pharmaceuticals, Inc.$18.41+4.66%

PGENPrecigen, Inc.

PGENPrecigen, Inc.$5.40-2.53%

SNDXSyndax Pharmaceuticals, Inc.

SNDXSyndax Pharmaceuticals, Inc.$20.81-1.89%

ATAIAtai Beckley Inc.

ATAIAtai Beckley Inc.$7.18+0.14%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

Questions About ORIC

What is the current price of ORIC Pharmaceuticals?

ORIC Pharmaceuticals is trading at $12.10 per share.

What is the 52-week range for ORIC Pharmaceuticals?

Over the past 52 weeks, ORIC Pharmaceuticals has traded between $7.23 and $14.93.

How much debt does ORIC Pharmaceuticals have?

As of the most recent reporting period, ORIC Pharmaceuticals reported total debt of $3.30M.

How much cash does ORIC Pharmaceuticals have on hand?

ORIC Pharmaceuticals reported $56.40M in cash and cash equivalents in its most recent financial results.

What is ORIC Pharmaceuticals’s dividend yield?

ORIC Pharmaceuticals does not currently have a dividend yield.

ORIC Pharmaceuticals(NASDAQ) ORIC

ORIC Pharmaceuticals Financials at a Glance

ORIC News

Why Shares of Oric Pharmaceuticals Jumped Monday

Why ORIC Pharmaceuticals Stock Is Crashing Today

Will Last Week's Biotech IPO Outperform in a Recession?

ORIC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ORIC Pharmaceuticals

What Is in the Medicine Cabinet?

How the Business Grew

Standing Out From the Crowd

By the Numbers

Bottom Line

ORIC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ORIC Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ORIC

What is the current price of ORIC Pharmaceuticals?

What is the 52-week range for ORIC Pharmaceuticals?

How much debt does ORIC Pharmaceuticals have?

How much cash does ORIC Pharmaceuticals have on hand?

What is ORIC Pharmaceuticals’s dividend yield?

Premium Investing Services